The Daily Toke

April 19, 2026

# Cannabis Policy Divides As Federal Rescheduling Looms

The federal government's move to reclassify cannabis from Schedule I to Schedule III represents a seismic shift in how Washington officially views the plant—finally acknowledging what millions of patients, researchers, and advocates have argued for decades: that cannabis has legitimate medical applications. This reclassification places cannabis alongside medications like ketamine, opening pathways for critical research that's been blocked for over 50 years under Nixon's 1970 Controlled Substances Act. Yet even as federal policy moves forward, state legislatures are choosing dramatically different paths, exposing a deep fracture in American cannabis politics.

The disconnect between public opinion and legislative action in Tennessee reflects a broader political reality: while medical cannabis programs now exist in nearly 40 states, prohibitionist legislatures are still fighting defensive battles against both constituents and federal momentum. The most glaring issue is how thoroughly these restrictive bills ignore real-world evidence and lived experience. Without a regulated framework, Tennessee patients currently lack any legal access to cannabis products, no safety standards, no quality control, and no legal protections—yet lawmakers argue that blocking a potential regulated program prevents chaos. 🤔 THINK ABOUT IT Alcohol kills approximately 95,000 Americans annually, prescription opioids kill more than 16,000 per year, and cannabis has zero recorded overdose deaths in human history. Yet cannabis remains federally scheduled as more dangerous than ketamine while alcohol and opioids remain legal and widely available.

Global cannabis law enforcement reflects the same political fragmentation. The United Arab Emirates, for example, maintains strict prohibition on both recreational and medical cannabis, though the country has recently eased minimum sentences for first-time drug possession from two years to three months and stopped automatically deporting non-citizens. 🚀 THIS IS COOL THC products like edibles are now destroyed rather than prosecuted as harshly, signaling gradual policy evolution even in traditionally restrictive jurisdictions. Yet the country remains dangerous for cannabis users; a U.S. citizen legally using cannabis in Nevada was arrested in the UAE in 2021 after cannabis appeared in a drug test, demonstrating that international prohibition gaps create real risks for travelers.

The science underlying cannabis's medical applications continues to advance. Cannabis contains over 120 distinct cannabinoids, with tetrahydrocannabinol (THC) producing the plant's characteristic psychoactive effects and cannabidiol (CBD) offering non-intoxicating therapeutic potential. 💰 MONEY MOVES The federal rescheduling could unlock substantial research funding, pharmaceutical development, and state-regulated market expansion—creating economic opportunities that prohibitionist states like Tennessee are now explicitly preventing their residents from accessing. Meanwhile, the National Institute on Drug Abuse continues funding research on cannabis's health effects, impacts on developing brains, mental health applications, and public health impacts of cannabis policy itself, building the evidence base that drives normalization forward.

What emerges from this landscape is a system in genuine transition. Federal reclassification signals that decades of prohibition were built on faulty premises, yet state-level resistance shows that political change lags scientific evidence and public opinion. Patients in Tennessee face impossible choices: suffer without legal relief, risk the black market, or travel to neighboring states. Meanwhile, in jurisdictions with regulated programs, patients access quality-controlled products with legal protections and clear dosing information. The political battle over cannabis is increasingly not about whether it has medical value—the federal government has settled that question—but about whether politicians will allow their constituents to access it legally.

April 19, 2026

Cannabis Business Tightens Regulations in New Jersey as Market Matures

New Jersey's cannabis market just entered a new phase of regulation. Governor Mikie Sherill signed Senate Bill 3945 into law last month, and it took effect this week, fundamentally reshaping how intoxicating hemp products move through the state's retail channels. 💰 MONEY MOVES Products containing more than 0.3 percent total THC—including delta-8, delta-10, THCA, and other naturally occurring intoxicating cannabinoids—are now exclusively available through licensed marijuana dispensaries, meaning they can no longer be purchased at gas stations, convenience stores, CBD shops, or smoke shops where they previously dominated shelf space. The change also prohibits online sales and vending machine distribution of these products to anyone under 21. The law creates a temporary window for hemp beverages under the Division of Alcoholic Beverage Control until November 13, when all intoxicating hemp products exceeding 0.4 milligrams of total THC must funnel exclusively into the state's licensed marijuana system.

The regulatory shift reflects a broader industry maturation: as cannabis normalization spreads across states, the distinction between "hemp" and "marijuana" is collapsing into administrative categories that track THC content rather than botanical identity. The New Jersey Cannabis Regulatory Commission has explicitly warned in-state hemp cultivators that if they plan to produce products exceeding the new April 13 limits, they must apply for marijuana cultivation or manufacturing licenses immediately—or face unlawful operation charges. This forces a clear choice: stay below the threshold and remain in the unregulated convenience-store economy, or go licensed and professional. 🚀 THIS IS COOL The move reflects genuine progress in how states approach cannabis science: regulators are now basing restrictions on actual cannabinoid profiles and dosing metrics rather than crude plant bans, treating the compound like a medicine or consumer product that can be measured, controlled, and distributed responsibly.

The timing aligns with pending federal hemp regulations expected to tighten on November 13—the same date New Jersey's permanent rules take effect. This synchronization suggests states are preparing for federal guidance that will likely harmonize interstate hemp commerce around THC thresholds and testing standards. For New Jersey's licensed marijuana retailers, this is significant: intoxicating hemp products that were previously scattered across thousands of retail touchpoints now consolidate into the state's controlled dispensary network. 💰 MONEY MOVES Licensed retailers gain exclusive access to an entire product category, potentially driving traffic and inventory turnover, while the state captures tax revenue and regulatory oversight of what was previously an unregulated gray market operating in plain sight at 7-Elevens and smoke shops.

What makes this moment worth examining: New Jersey is effectively admitting that hemp-derived intoxicating products are indistinguishable from marijuana in their effects and consumer appeal. The law doesn't ban them—it just routes them through the licensed system. This is pragmatism disguised as regulation. Rather than pretending the products don't exist or pose regulatory challenges, the state is saying: fine, they're legal, they're going to be sold, so let's control how and where. The parallel to alcohol regulation is instructive. Nobody tries to sell intoxicating beverages at gas stations and convenience stores without licensing, taxation, and age verification. Cannabis in New Jersey is now approaching that same framework, except the hemp beverage exemption creates a brief window where producers and retailers can pivot their operations.

🤔 THINK ABOUT IT Cannabis science now recognizes over 120 cannabinoids with distinct pharmacological effects, yet federal policy still treats the entire plant as Schedule I—meaning "no accepted medical use." Meanwhile, the FDA has already approved Epidiolex, a CBD-derived epilepsy medication. States are writing regulations around delta-8, delta-10, and THCA as consumer products. Medical patients use cannabis for chronic pain, glaucoma, and appetite support in licensed programs nationwide. So if the compounds are real enough to regulate, measure, and tax, and real enough for physicians to recommend, why hasn't federal classification caught up to state reality?

The New Jersey restrictions take effect as the broader cannabis business matures from gray-market chaos toward standardized retail infrastructure. Licensed operators now have clearer rules. State regulators have better control over supply chains. Consumers get tested products with labeled dosages. It's not legalization theater—it's the slow, administrative normalization of a plant that's been around for millennia and is now generating billions in documented economic activity across North America.

April 19, 2026

# Hemp Ban Watch: Columbus Data Gaps and National Hemp Status

Unable to assess hemp policy developments in Columbus, Ohio. The City of Columbus website snippets provided—covering water services, parks and recreation, and general city portals—contain no public statements, ordinances, or regulatory filings related to hemp cultivation, sales, or possession. A permit application for the Parsons & Kossuth Apartments project at 870 Parsons Avenue shows standard municipal permitting infrastructure, but does not reference hemp policy. The Columbus City Attorney's office homepage emphasizes "protecting public health and safety" but offers no specific cannabis or hemp guidance in available materials. Without access to city council meeting minutes, ordinance databases, or official enforcement records, we cannot confirm whether Columbus is pursuing hemp restrictions, maintaining current regulations, or planning policy changes.

Nationally, the legal landscape remains clear: hemp is federally legal. 🚀 THIS IS COOL The 2018 Agricultural Improvement Act (Farm Bill) removed hemp from the federal controlled substances list, making industrial hemp cultivation legal across the United States—provided growers obtain permits and states establish approved regulatory programs. Hemp—defined as Cannabis sativa L. with less than 0.3% THC by dry weight—has no psychoactive properties and serves documented applications in nutrition, textiles, biomaterials, and fuel production. The National Hemp Association notes that hemp grows in over 30 countries worldwide and requires minimal fertilizer and pesticides compared to conventional crops, with deep-rooted plants naturally restoring soil nitrogen and minerals.

The distinction between industrial hemp and marijuana remains scientifically straightforward but politically contentious in some jurisdictions. Industrial hemp contains virtually no THC and produces no intoxicating effects—hemp seeds contain zero THC and are sold as nutritional supplements. Yet some states and municipalities have delayed or blocked hemp programs despite federal legalization, citing enforcement concerns or conflating low-THC hemp with high-THC cannabis products. These delays often contradict stated public health priorities, since hemp seed protein rivals human blood protein in amino acid composition and hemp seed oil provides essential fatty acids linked to cardiovascular health.

🤔 THINK ABOUT IT If Columbus is considering hemp restrictions, the city would be moving against federal law and documented agricultural science—potentially blocking access to a crop that requires fewer chemical inputs than corn or soybeans, restores soil health, and provides nutritional alternatives for populations with food security or digestive concerns. The permits and regulatory infrastructure already exist at the federal and state levels. Local bans would primarily affect farmers, processors, and consumers in that jurisdiction while leaving federal legality and neighboring markets unaffected.

We will continue monitoring Columbus city council proceedings, ordinance updates, and official statements for any hemp-specific policy announcements. Until then, the city's hemp status remains undefined—neither explicitly banned nor actively promoted in publicly available documents.

April 19, 2026

# THC in Science: Clinical Trials Meet Regulatory Momentum

Researchers are launching a new wave of clinical trials to determine what marijuana actually does—and doesn't do—as medicine, even as the scientific community grapples with a stark reality: most medical cannabis claims lack rigorous evidence. A major review in The New York Times found little documented benefit for most conditions, while parallel research published in Newswise confirms that evidence is lacking across the board for the vast majority of medical cannabis applications. Yet this moment of scientific scrutiny coincides with real momentum on the regulatory side. Trump's December 2025 reclassification of cannabis and CBD compounds signals a potential shift in how federal law treats these substances, potentially opening doors for the long-delayed research that might finally answer the questions doctors have been asking for decades.

The research gap is real and measurable. 🚀 THIS IS COOL UCHealth and other institutions are now running controlled clinical trials to isolate what THC and CBD actually accomplish therapeutically—moving beyond anecdotes and toward evidence. One bright spot emerging from the data involves chronic pain: ScienceDaily's reporting on cannabis and pain management suggests the plant does have genuine application in this specific area, even as broader claims remain unproven. This distinction matters. Without clinical rigor, patients and doctors can't distinguish between marketing hype and actual therapeutic benefit. The trials underway now are designed to fix that, condition by condition, cannabinoid by cannabinoid.

💰 MONEY MOVES The reclassification matters for more than just research—it matters for market access and industry investment. Moving cannabis from Schedule I (defined as having no accepted medical use) to a lower classification removes federal barriers that have frozen out legitimate researchers, pharmaceutical development, and clinical infrastructure for over fifty years. When the Shafer Commission recommended decriminalization back in 1970, Nixon rejected the advice and locked cannabis into Schedule I anyway. That decision created a half-century bottleneck on the very research we're now desperately trying to do. A reclassification opens the spigot for funding, FDA pathways, and academic collaboration—all things that haven't been possible under full federal prohibition.

The stakes are especially high for seniors and veterans. Trump's reclassification could reshape how older Americans and service members access cannabis-based treatment for chronic pain, PTSD, and anxiety. Many veterans already use legal THC products in states where they're available, and the lack of federal clarity has created a patchwork where geography determines access to care. 🤔 THINK ABOUT IT We've spent over five decades blocking research into a plant with zero recorded overdose deaths in human history, while prescription opioids kill 16,000+ Americans per year and alcohol kills roughly 95,000. How many clinical trials could we have completed in that time? How many patients could have had real answers instead of guesses?

The trials launching now will finally provide those answers—assuming they're actually funded and completed. The path forward requires two things: consistent federal clarity on research status, and commitment to letting the evidence lead rather than ideology. Britannica's comprehensive review of the medical marijuana debate shows just how polarized this conversation has become, with genuine therapeutic potential obscured by politics from both directions. What we need now is boring, rigorous science. What we're finally getting is the possibility of it. The next 18 to 36 months of clinical data will matter far more than the previous fifty years of prohibition and conjecture combined.

April 19, 2026

Texas cannabis advocates are watching closely as neighboring states tighten regulations around hemp-derived intoxicating products, a pattern that could signal what enforcement looks like if federal rescheduling finally moves forward. New Jersey's Senate Bill 3945 took effect Monday, reclassifying hemp products containing more than 0.3 percent total THC—including delta-8, delta-10, and THCA—as marijuana, available only through licensed dispensaries. Colorado's Marijuana Enforcement Division simultaneously announced a crackdown on companies illegally selling cheaper hemp products as marijuana, citing "serious risks to public safety, market integrity and the tax revenue framework" for the state's regulated cannabis industry. Both moves reflect a growing regulatory squeeze on the uncontrolled hemp market that has flourished in states where cannabis remains federally illegal.

The tension runs deeper than simple compliance. Creating liquid distillate for vapes and edibles from hemp costs significantly less than using marijuana, giving manufacturers a competitive advantage that threatens tax revenue in regulated states. But Colorado regulators have documented serious safety concerns: manufacturers rely on toxic chemicals like methylene chloride—banned by the EPA and Colorado itself—to convert CBD into THC. In 2024, investigators found popular marijuana vapes sold in dispensaries contaminated with that exact chemical. One company, Ware Hause, surrendered its marijuana license in response. 💰 MONEY MOVES When unregulated hemp products undercut licensed cannabis sales, states lose tax revenue that funds education, healthcare, and drug treatment programs, while consumers face products potentially contaminated with banned solvents.

Meanwhile, at the federal level, momentum on cannabis rescheduling appears stalled. President Trump complained Saturday that the Department of Justice is "slow-walking" him on moving marijuana from Schedule I to Schedule III—an order he issued four months ago that still hasn't been executed.

For Texas, these developments matter enormously. Texas currently allows only low-THC cannabis for specific medical conditions and has no legal recreational market. The hemp-derived product boom that Colorado and New Jersey are now restricting has created a gray market where consumers purchase delta-8, delta-10, and other intoxicating cannabinoids online and in smoke shops—products that exist in federal and state legal limbo. If federal rescheduling happens and states follow New Jersey and Colorado's lead, that entire market could collapse overnight, or shift into the regulated cannabis system. 🤔 THINK ABOUT IT Colorado banned intoxicating hemp products years ago, yet manufacturers still found ways to exploit regulatory gaps and sell contaminated products through dispensaries—what enforcement gaps might Texas face if federal rescheduling suddenly forces it to build a regulated adult-use market from scratch?